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Oral misoprostol has been widely discussed as a method of labour induction. It is recommended for this indication by the WHO, FIGO, and SOGC ADDIN EN.CITE 1-3. A systematic review comparing misoprostol with Foley catheter and dinoprostone induction agents suggests that “Oral misoprostol for the induction of labour is safer than vaginal misoprostol and has the lowest rate of caesarean section”.4 A recently completed UK National Institute of Health Research (NIHR) IHR funded network and cost-effectiveness analysis included 31 induction regimes evaluated in 611 trials with over 100,000 trial participants. Titrated low-dose oral misoprostol was identified as likely to be the most cost-effective.5 This recent evidence is in contrast with the current NICE guidelines that have not recommended the use of misoprostol, citing that misoprostol is not labelled for labour induction  and that accurate concentrations and reliable drug delivery cannot be guaranteed given that low dose formulations are not available.6

‘Oral misoprostol’, however, is not a single entity and systematic reviewers have struggled to cope with the wide variation in protocols (table 1). Published randomised trials have a wide variety of misoprostol doses (20-200mcg) and frequency of administration (1-6 hourly). Some protocols use a single dose for the whole induction period, while others escalate the dose until the desired effect is achieved. Some use misoprostol purely for cervical ripening and replace it with an oxytocin infusion once membrane rupture is feasible, while others use oral misoprostol continuously until delivery. But the variation doesn’t stop there. Until recently there was no commercially produced low dose misoprostol tablet, and so clinicians developed their own ways of preparing and administering the intended dose. Some practitioners divided the small and notoriously crumbly 200 or 100 mcg tablets into fragments. Others made up 1mcg/ml solutions by dissolving tablets in tap water. It is only recently that commercially available 25mcg tablets have become available (Cipla, India) and these are not widely available outside of India. 

Is there evidence to suggest that any of these protocols are superior? Subgroup analyses of some important clinical outcomes show a clear dose effect. For example, when comparing oral misoprostol with dinoprostone, the rate of hyperstimulation increases as the initial dose rises from 25 to 200mcg.4   It would therefore appear that there are safety benefits of using doses of 20-25mcg, even if they may result in a slower induction process. This is supported by a systematic review of just the studies that used 20-25 mcg of oral misoprostol, which found a lower CS rate and lower hyperstimulation rates compared with standard induction methods. ADDIN EN.CITE 24 And while, in previous studies researchers have been forced to either use cut 200mcg tablets or solution, high quality 25mcg tablets are now available. These have recently been confirmed to be effective induction agents (better than Foley catheter) when given orally in a large MRC induction study.25

The use of regimens in which misoprostol is given every 1-2 hours is supported by pharmacokinetic studies which show that oral misoprostol reaches its peak serum level in 30 minutes, but that its half-life is only 90 minutes as misoprostol acid is rapidly metabolised by the liver and excreted by the kidneys.26 The 4-6 hourly dosage regimens have stemmed from an incorrect assumption that the oral pharmacokinetic data is the same as that for vaginal doses.26 

It remains untested whether the low dose of oral misoprostol will perform better if titrated to clinical response, and whether there are benefits of continuing its use through to the end of labour. Most studies have used oxytocin to continue with the induction process once cervical ripening is complete. There is no question, that there are considerable logistic and safety challenges with both approaches, particularly in low resource settings. 

Oxytocin infusions are notorious for causing hyperstimulation, especially when, as in many parts of the world, they are used without electronic rate controllers. In settings where labour ward staff numbers are very limited, an oxytocin infusion can run unsupervised for many hours without a member of staff checking on its rate or effect on uterine contractions.27 In contrast, a titrated oral dose of misoprostol needs to be regularly administered by a trained member of staff, a factor that forces some kind of regular clinical assessment and stops the induction process in the absence of staff.  So there may also be organisational and safety benefits to the use of low dose oral misoprostol over oxytocin in low resource settings. This is supported by a recent randomised trial of oxytocin versus oral misoprostol 20mcg solution given every 2 hours which found no difference in major outcomes, but reduced rates of hyperstimulation in the misoprostol group.28

What is the way forward? Although off-label drug use remains essential in pregnancy (for example with betamethasone for fetal lung maturation), clinicians continue to worry about using an off-label drug when labelled alternatives are available.  The development or import of a commercially available 25mcg tablet licensed for labour induction would therefore be a major advance and provide a definitive protocol. Until that time we recommend the use of 25mcg tablets or solution used every 1-2 hours. It appears to be safe to use it up to the time of birth rather than simply for cervical ripening. However, use of this ‘extended’ protocol should include close observation and use of acute tocolytics when hyperstimulation is suspected. Although there are no formal evaluations of its benefit, a careful, stepped increase in misoprostol dose to 50 mcg, particularly in nulliparous women would also seem appropriate in those who do not respond to the initial doses.  

Ideally, formal pharmacokinetic studies would help clarify the differences between tablets and oral solution and to establish the optimal frequency of the lowest effective dose. Regrettably, such studies are unlikely to be supported by pharmaceutical companies as misoprostol is too cheap to justify the investment. Misoprostol’s image as an abortion drug also does not help, despite the fact that its uterotonic properties are life-saving in many low resource settings. Whether public funders in high resource settings will rise to the challenge remains to be seen. A large study of a combination of titrated low dose oral misoprostol followed by oxytocin in active phase of laboue versus titrated oral misoprostol alone given until birth seems an obvious way forward.
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Table 1. Published trials of labour induction using low-dose (<50mcg) oral misoprostol

Initial dose (mcg)	Formulation	Dosing interval, hours	Max. single dose, mcg (vol.)	Continued in active phase?	References
5	Titrated low-dose solution	1	20 (20ml)	Not stated	Dodd 2006a7
10	Titrated low-dose solution	4	20 (20ml)	No	Majoko 2002 ADDIN EN.CITE 8
20	Titrated low-dose solution	1	50 (50ml)	No	Rouzi 20149
			80 (40ml)	No	Souza 201310
			40 (40ml)	No	Thaisomboon 201211
			60 (60ml)	Yes, only if augmentation required	Cheng 200812
	Fixed low-dose solution	2	40 (40ml)	Yes, only if augmentation required	Hofmeyr 200113
			40 (40ml)	Yes	Dallenbach 2003 ADDIN EN.CITE 14
			20 (20ml)	Yes	Dodd 200615
	Fixed low-dose solution	2	20 (20ml)	No	Moodley 2003  ADDIN EN.CITE 16
25	Fixed low-dose solution	2	25 (25ml)	No	Aalami-Harandi 2013 ADDIN EN.CITE 17
	Tablet 	2	50	Yes	Bricker 2008 ADDIN EN.CITE 18
		3	25	Yes	De 200619
		4	100	No	Henrich 2008 ADDIN EN.CITE 20
			25	No	How 200121
		72	25	No	Kipikasa 200522
30	Fixed low-dose solution	1	30 (30ml)	No	Zvandasara 200823




